• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Neoplasms, Basal Cell

Neoplasms, Basal Cell - 16 Studies Found

Completed : CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
:
  • Carcinoma, Basal Cell
  • Carcinoma, Squamous Cell
  • Skin Neopla
    : 2009-02-18
    :
    • Drug: 5-fluorouracil Apply thi

Completed : Use of Otoscope as a Non-Invasive Tool for Diagnosis of Pilomatricoma
: Pilomatrixoma
: 2008-07-11
Completed : Clinical Trial Comparing Tissue Adhesive Vs. Absorbable Suture Vs. Non-Absorbable Suture
:
  • Cyst of Face, Neck or Shoulder
  • Pilomatrixoma of Face, Neck or Shoulder

: 2006-02-15
: Device: standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)
Not yet recruiting : Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
: Basal Cell Carcinoma
: 2016-12-26
: Drug: Vismodegib 1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
Completed : Vismodegib on Locally Advanced and Metastatic Basal Cell Carcinoma Under Real World Conditions
: Metastatic Basal Cell Carcinoma
: 2016-04-24
Completed : Topical Itraconazole in Treating Patients With Basal Cell Cancer
: Skin Basal Cell Carcinoma
: 2016-03-31
:
  • Drug: Itraconazole Applied top

Not yet recruiting : Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
: Skin Basal Cell Carcinoma
: 2016-03-01
:
  • Drug: Arsenic Trioxide Given P

Recruiting : Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
: Skin Basal Cell Carcinoma
: 2016-02-12
:
  • Other: Laboratory Biomarker Analysis

Completed : Observational Study to Determine the Effectiveness and Safety of Vismodegib in Patients With Locally Advanced Basal Cell Carcinoma (laBCC)
: Locally Advanced Basal Cell Carcinoma
: 2016-02-02
: Drug: Vismodegib Dosing of Vismodegib in accordance with local clinical practice and local labeling
Active, not recruiting : Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
: Basal Cell Carcinoma
: 2016-01-20
: Drug: ERIVEDGE Other Name: VISMODEGIB
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.